A Randomized, Open-label, Multi-center, Phase 3, 2-arm Study Evaluating the Efficacy and Safety of Peg Interferon Alfa-2b Low-dose Maintenance Monotherapy Versus Standard Supportive Care in Patients With Cirrhotic Hepatitis C Co-infected With Human Immunodeficiency Virus - The ENDURE Study.

Trial Profile

A Randomized, Open-label, Multi-center, Phase 3, 2-arm Study Evaluating the Efficacy and Safety of Peg Interferon Alfa-2b Low-dose Maintenance Monotherapy Versus Standard Supportive Care in Patients With Cirrhotic Hepatitis C Co-infected With Human Immunodeficiency Virus - The ENDURE Study.

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 10 Oct 2014

At a glance

  • Drugs Peginterferon alfa-2a (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms ENDURE
  • Sponsors Merck Sharp & Dohme; Schering-Plough
  • Most Recent Events

    • 19 Jun 2007 Status changed from planning to withdrawn prior to recruitment.
    • 18 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top